755 related articles for article (PubMed ID: 15301874)
21. [Prognosis after complete surgical resection for non-small cell lung cancer based on the staging classification].
Pfannschmidt J; Muley T; Hoffmann H; Bülzebruck H; Dienemann H
Dtsch Med Wochenschr; 2006 Nov; 131(47):2643-8. PubMed ID: 17109272
[TBL] [Abstract][Full Text] [Related]
22. Accelerated induction therapy and resection for poor prognosis stage III non-small cell lung cancer.
Rice TW; Adelstein DJ; Koka A; Tefft M; Kirby TJ; Van Kirk MA; Taylor ME; Olencki TE; Peereboom D; Budd GT
Ann Thorac Surg; 1995 Sep; 60(3):586-91; discussion 591-2. PubMed ID: 7677484
[TBL] [Abstract][Full Text] [Related]
23. Unresected stage III non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.
Okawara G; Rusthoven J; Newman T; Findlay B; Evans W
Cancer Prev Control; 1997 Aug; 1(3):249-59. PubMed ID: 9765750
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
[TBL] [Abstract][Full Text] [Related]
25. [A phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non squamous, non-small cell lung cancer (NSCLC)].
Tredaniel J; Mornex F; Barillot I; Diaz O; Hennequin C; Le Pechoux C; Lavole A; Giraud P; Souquet PJ; Teixeira L; Vaylet F; Zalcman G; Baudrin L; Morin F; Milleron B
Rev Mal Respir; 2011 Jan; 28(1):51-7. PubMed ID: 21277474
[TBL] [Abstract][Full Text] [Related]
26. Randomized phase 2 evaluation of preoperative radiation therapy and preoperative chemotherapy with mitomycin, vinblastine, and cisplatin in patients with technically unresectable stage IIIA and IIIB non-small cell cancer of the lung. LCSG 881.
Wagner H; Lad T; Piantadosi S; Ruckdeschel JC
Chest; 1994 Dec; 106(6 Suppl):348S-354S. PubMed ID: 7988262
[TBL] [Abstract][Full Text] [Related]
27. Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study.
Berghmans T; Ameye L; Willems L; Paesmans M; Mascaux C; Lafitte JJ; Meert AP; Scherpereel A; Cortot AB; Cstoth I; Dernies T; Toussaint L; Leclercq N; Sculier JP;
Lung Cancer; 2013 Nov; 82(2):340-5. PubMed ID: 24007627
[TBL] [Abstract][Full Text] [Related]
28. The effect of radiation dose and chemotherapy on overall survival in 237 patients with Stage III non-small-cell lung cancer.
Wang L; Correa CR; Zhao L; Hayman J; Kalemkerian GP; Lyons S; Cease K; Brenner D; Kong FM
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1383-90. PubMed ID: 18929449
[TBL] [Abstract][Full Text] [Related]
29. Alternated approach with local irradiation and combination chemotherapy including cisplatin or carboplatin plus epirubicin and etoposide in intermediate stage non-small cell lung cancer.
Comella P; Scoppa G; Daponte A; Musetta G; Anania C; Maiorino A; Curcio C; Casaretti R; Comella G
Cancer; 1994 Oct; 74(7):1874-81. PubMed ID: 8082093
[TBL] [Abstract][Full Text] [Related]
30. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Furuse K; Fukuoka M; Kawahara M; Nishikawa H; Takada Y; Kudoh S; Katagami N; Ariyoshi Y
J Clin Oncol; 1999 Sep; 17(9):2692-9. PubMed ID: 10561343
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant etoposide, ifosfamide, and cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancer.
Pujol JL; Lafontaine T; Quantin X; Reme-Saumon M; Cupissol D; Khial F; Michel FB
Chest; 1999 Jan; 115(1):144-50. PubMed ID: 9925076
[TBL] [Abstract][Full Text] [Related]
32. Alternating radiotherapy and chemotherapy for inoperable Stage III non-small-cell lung cancer: long-term results of two Phase II GOTHA trials. Groupe d'Oncologie Thoracique Alpine.
Mirimanoff RO; Moro D; Bolla M; Michel G; Brambilla C; Mermillod B; Miralbell R; Alberto P
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):487-94. PubMed ID: 9806505
[TBL] [Abstract][Full Text] [Related]
33. Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party.
Sculier JP; Paesmans M; Thiriaux J; Lecomte J; Bureau G; Giner V; Efremidis A; Lafitte JJ; Berchier MC; Alexopoulos CG; Zacharias C; Mommen P; Ninane V; Klastersky J
J Clin Oncol; 1998 Apr; 16(4):1388-96. PubMed ID: 9552042
[TBL] [Abstract][Full Text] [Related]
34. Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials.
Mouillet G; Monnet E; Milleron B; Puyraveau M; Quoix E; David P; Ducoloné A; Molinier O; Zalcman G; Depierre A; Westeel V;
J Thorac Oncol; 2012 May; 7(5):841-9. PubMed ID: 22722786
[TBL] [Abstract][Full Text] [Related]
35. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial.
Liang J; Bi N; Wu S; Chen M; Lv C; Zhao L; Shi A; Jiang W; Xu Y; Zhou Z; Wang W; Chen D; Hui Z; Lv J; Zhang H; Feng Q; Xiao Z; Wang X; Liu L; Zhang T; Du L; Chen W; Shyr Y; Yin W; Li J; He J; Wang L
Ann Oncol; 2017 Apr; 28(4):777-783. PubMed ID: 28137739
[TBL] [Abstract][Full Text] [Related]
36. Pathological response and prognosis of stage III non-small cell lung cancer patients treated with induction chemoradiation.
Isobe K; Hata Y; Sakaguchi S; Sato F; Takahashi S; Sato K; Sano G; Sugino K; Sakamoto S; Takai Y; Mitsuda A; Terahara A; Shibuya K; Takagi K; Homma S
Asia Pac J Clin Oncol; 2012 Sep; 8(3):260-6. PubMed ID: 22897895
[TBL] [Abstract][Full Text] [Related]
37. Mitomycin, ifosfamide, cisplatin for non-small cell lung cancer: an implementation study.
Berghmans T; Meert AP; Ninane V; Sculier JP
Monaldi Arch Chest Dis; 2005 Dec; 63(4):184-92. PubMed ID: 16454217
[TBL] [Abstract][Full Text] [Related]
38. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer.
Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Wenger M; Lange W; Mertelsmann R
Ann Oncol; 1997 Jan; 8(1):57-64. PubMed ID: 9093708
[TBL] [Abstract][Full Text] [Related]
39. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1).
Booton R; Lorigan P; Anderson H; Baka S; Ashcroft L; Nicolson M; O'Brien M; Dunlop D; O'Byrne K; Laurence V; Snee M; Dark G; Thatcher N
Ann Oncol; 2006 Jul; 17(7):1111-9. PubMed ID: 16603599
[TBL] [Abstract][Full Text] [Related]
40. [Prognostic analysis of curative surgery for stage IIIA-N2 non-small cell lung cancer].
Liu JW; Li J; Lin G; Shang XQ
Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):50-3. PubMed ID: 23648301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
